Reduced Estradiol-Induced Vasodilation and Poly-(ADP-Ribose) Polymerase (PARP) Activity in the Aortas of Rats with Experimental Polycystic Ovary Syndrome (PCOS)

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Masszi, Gabriella ^a   Horvath, Eszter Maria ^b   Tarszabo, Robert ^b   Benko, Rita ^b   Novak, Agnes ^a   Buday, Anna ^b   Tokes, Anna Maria ^b   Nadasy, Gyorgy L ^b   Hamar, Peter ^b   Benyó, Zoltán ^b   Varbiro, Szabolcs ^b  

^a BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CALCITRIOL; ESTRADIOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ACUTE DRUG ADMINISTRATION; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; IMMUNOHISTOCHEMISTRY; ISOLATED ARTERY; MYOGRAPHY; NONHUMAN; OVARY POLYCYSTIC DISEASE; RAT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; AORTA; CHOLECALCIFEROL; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGENS; FEMALE; MUSCLE, SMOOTH, VASCULAR; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; POLYCYSTIC OVARY SYNDROME; RATS; RATS, WISTAR; VASOCONSTRICTION; VASODILATION; VITAMINS;

RATTUS; RODENTIA;

EID: 84875410764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055589     Document Type: Article

References (40)

1. American Association of Clinical Endocrinologists (2005) Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome Endocrine Practice Vol.11 No.2.
2. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, et al. (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab (955) (): 2038-2049.
3. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, et al. (2003) Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab (886) (): 2562-2568.
4. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P, (2000) Internal carotid artery haemodynamics in women with polycystic ovaries. Clin. Sci. (Lond). 98: 661-665.
5. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, et al. (2005) Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 90: 5088-5095.
6. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM, (2011) PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update (174) (): 495-500.
7. Mendelsohn ME, Karas RH, (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811.
8. Cignarella A, Paelotti R, Puglisi L, (2001) Direct effects of estrogen on the vessel wall. Med Res Rev. 21: 171-184.
9. Firouzabadi R, Aflatoonian A, Modarresi S, Sekhavat L, Mohammad Taheri S, (2012) Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complement Ther Clin Pract May 18(2): 85-88.
10. Ardabili HR, Gargari BP, Farzadi L, (2012) Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. Mar 32(3): 195-201.
11. Virág L, (2005) Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr. Vasc. Pharmacol 3: 209-214.
12. Pacher P, Szabó C, (2007) Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 25: 235-260.
13. Pacher P, Szabó C, (2008) Role of the peroxynitrite-poly(ADP ribose) polimerase pathway in human disease. Am J Pathol. 173: 2-13.
14. Tóth-Zsámboki E, Horváth E, Vargova K, Pankotai E, Murthy K, et al. (2006) Activation of poly(ADP-ribose) polymerase by myocardial ischaemia and coronary reperfusion in human circulating leukocytes. Mol Med 12 221-228: 4.
15. Yao L, Huang K, Huang D, Wang J, Guo H, (2008) Acute myocardial infarction induced increases in plasma tumor necrosis factor-alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell. Liao Int. J. Cardiol (123) (): 366-368.
16. Molnár A, Toth A, Bagi Z, Papp Z, Edes I, et al. (2006) Activation of the poly(ADP-ribose) polymerase pathway in human heart failure. Mol Med (12) (): 143-152.
17. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabó C, (2001) Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase. Circ Res. 89: 684-691.
18. Szabo C, Pacher P, Swanson RA, (2006) Novel modulators of poly(ADP-ribose)polymerase. Trends Pharmacol Sci. 27: 626-30.
19. Jog NR, Dinall JA, Gllucci S, Madaio MP, Caricchio R, (2009) Poly(ADP-Ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death an modulating inflammation. J Immunol, Jun 1 182(11): 7297-7306.
20. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, et al. (2009) A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis. 27(4): 359-64.
21. Mabley JG, Wallace R, Pacher P, Murphy K, Szabó C, (2007) Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int J Mol Med. 19: 947-952.
22. Mabley JG, Horvath E, Murthy KG, Zsengeller Z, Vaslin A, et al. (2005) Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J. Pharmacol. Exp. Ther. 315(2): 812-820.
23. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD, (2005) Ischemic nitric oxide and poly(ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab (25) (): 502-512.
24. Yuan M, Siegel C, Zeng Z, Li J, McCullough LD, (2009) Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol. 217(1): 210-218.
25. Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, et al. (2007) A New Rat Model Exhibiting Both Ovarian and Metabolic Characteristics of Polycystic Ovary Syndrome. Endocrinology. 148: 3781-3791.
26. Przybylski R, Mccune S, Hollis B, Simpson RU, (2010) Vitamin D deficiency in the spontaneously hypertensive heart failure [SHHF] prone rat. Nutr Metab Cardiovasc Dis. 20: 641-6.
27. Buday A, Orsy P, Godó M, Mózes M, Kökény G, et al. (2010) Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(-/-) mice. Am J Physiol Heart Circ Physiol 299: H386-395.
28. Horváth EM, Benko R, Kiss L, Murányi M, Pék T, et al. (2009) Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia. 52: 952-961.
29. Horvath EM, Zsengellér ZK, Szabo C, (2011) Quantification of PARP activity in human tissues: ex vivo assays in blood cells and immunohistochemistry in human biopsies. Methods Mol Biol. 780: 267-275.
30. Orshal JM, Khalil RA, (2004) Gender. sex hormones and vascular tone. Am J Physiol Regul Integr Comp Physiol. 286: 233-249.
31. Miller VM (2010) Sex-based differencies in vascular function. Women's Health. 6; 737-752.
32. Andersen HL, Weis JU, Fjalland B, Korsgaard N, (1999) Effect of acute and long-term treatment with 17-beta-estradiol on the vasomotor responses in rat aorta. Br J Pharmacol. 126: 159-168.
33. Perusquia M, Stallone JN, (2010) Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolits. Am J Physiol Heart Circ Physiol. 298: 1301-1307.
34. Torres IP, El Hafidi M, Zamora-González J, Infante O, Chavira B, et al. (2007) Modulation of aortic vascular reactivity by sex hormones in a male rat model of metabolic syndrome. Life Sci. 80: 2170-2180.
35. New G, Berry KL, Cameron JD, Harper RW, Meredith IT, (2000) Long-term oestrogen treatment does not alter systemic arterial compliance and haemodynamics in biological males. Coron Artery Dis. 11: 253-259.
36. Li M, Kuo L, Stallone JN, (2008) Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression. Am J Physiol Heart Circ Physiol. 294: H2444-2455.
37. Xu Z, Hu L, Cheng L, Qian Y, Yang Y, (2010) Dihydrotestosterone protects human vascular endothelial cells from H2O2-induced apoptosis through inhibition of caspase-3, caspase-9 and p38 MAPK. European Journal of Pharmacology. 643: 254-259.
38. Virag L, Szabo C, (2002) The therapeutic potential of poly(ADP-ribose)polymerase inhibitors. Pharmacol Rev. 54: 375-429.
39. Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, Järvelä I, et al. (2011) Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 96: 1827-1834.
40. Erdélyi K, Bakondi E, Gergely P, Szabó C, Virág L, (2005) Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell Mol Life Sci. 62: 751-759.